The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by UBS on January 16, 2025. The analyst firm set a price target for $738.00 expecting REGN to rise to within 12 months (a possible 9.33% upside). 72 analyst firms have reported ratings in the last year.

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by UBS, and Regeneron Pharmaceuticals downgraded their neutral rating.

The last upgrade for Regeneron Pharmaceuticals Inc happened on January 12, 2024 when RBC Capital raised their price target to $1076. RBC Capital previously had a sector perform for Regeneron Pharmaceuticals Inc.

The last downgrade for Regeneron Pharmaceuticals Inc happened on January 16, 2025 when UBS changed their price target from $1130 to $738 for Regeneron Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on January 16, 2025 so you should expect the next rating to be made available sometime around January 16, 2026.

While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a downgraded with a price target of $1130.00 to $738.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $675.00, which is out of the analyst’s predicted range.